Myasthenia gravis and risks for comorbidity

Area of Science:

• Neurology
• Immunology
• Autoimmune Diseases

Background:

• Myasthenia gravis (MG) is an autoimmune disorder characterized by skeletal muscle weakness and fatigability.
• MG is classified into subgroups based on autoantibodies, thymus pathology, and clinical presentation.
• MG patients exhibit an increased risk for concordant autoimmune diseases, particularly early-onset MG.

Purpose of the Study:

• To review the spectrum of comorbidities associated with myasthenia gravis.
• To highlight the diagnostic and therapeutic challenges posed by comorbidities in MG patients.
• To emphasize the importance of accurate diagnosis and follow-up for coexisting conditions.

Main Methods:

• Literature review of studies on myasthenia gravis and its associated conditions.
• Analysis of reported comorbidities, including autoimmune diseases, cancers, and infections.
• Examination of treatment implications and safety of procedures like thymectomy.

Main Results:

• Common comorbidities include thyroid disease, systemic lupus erythematosus, and rheumatoid arthritis.
• While some cardiac issues and cancers (lymphomas) are reported with increased frequency, they do not represent a major threat in most cases.
• Severe muscle weakness increases risks of respiratory failure and infections; drug treatments can cause side effects.

Conclusions:

• Non-MG-related comorbidities present significant diagnostic and therapeutic challenges, especially in elderly patients.
• Thymectomy is generally a safe procedure with positive short- and long-term outcomes.
• Optimal diagnostic accuracy and follow-up are crucial for managing the complex health needs of MG patients with comorbidities.